
94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
ORIGINAL RESEARCH article
Front. Vet. Sci.
Sec. Veterinary Pharmacology and Toxicology
Volume 12 - 2025 | doi: 10.3389/fvets.2025.1556975
The final, formatted version of the article will be published soon.
You have multiple emails registered with Frontiers:
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
This study investigated the pharmacokinetics, safety, and tolerability of a full-spectrum CBDdominant oil formulated in medium-chain triglycerides (MCT oil) after a single intravenous (IV) administration, a single oral (PO) administration, and multiple oral administrations of CBD at a dose of 2.2 mg/kg in adult male and female beagle dogs.The CBD-dominant extract was administered to adult, intact beagle dogs (male n=4, female n=2) once intravenously, once orally, and every 12 hours orally for 21 days at a dose of 2.2 mg CBD/kg body weight (BW). Blood samples were collected at predetermined times to measure concentrations of serum CBD, 7-hydroxy-CBD (7-OH-CBD), 7-nor-7-carboxy-CBD (7-COOH-CBD), 9 -tetrahydrocannabinol ( 9 -THC), 11-hydroxy-THC (11-OH-THC), and 11carboxy-THC (11-COOH-THC). Serum CBD and 9 -THC concentrations were analyzed to estimate various pharmacokinetic parameters. Selected physical, behavioral, hematologic, and blood chemical measurements were obtained before and during single and repeated dose administrations.Pharmacokinetics of CBD after IV administration indicated a median (range) systemic clearance (CL) of 7.06 (6.14-10.5) mL/min/kg, a steady-state volume of distribution (Vss) of 2.13 (1.10-2.85) L/kg, and a half-life of 291 (183-508) minutes. The median (range) extent of systemic availability of CBD after a single oral dose was 31.2 (17.7-35.7) %.Pharmacokinetics of 9 -THC after IV administration were characterized by a CL of 8.85 (6.88-14.4) mL/min/kg, Vss of 1.98 (1.30-2.30) L/kg, and a half-life of 169 (139-476) minutes. The extent of systemic availability of 9 -THC after PO administration was 40.9 (20.5-46.2) %. The test article was well tolerated in all dogs during the study. Although serum alkaline phosphatase concentrations increased during the repeated PO dose study, they remained within normal limits.Both CBD and 9 -THC were rapidly cleared after IV administration and exhibited extensive volumes of distribution. Comparison of clearance to serum hepatic blood flow estimated the hepatic extraction ratio and extent of first pass metabolism after PO administration, which was confirmed by analyzing the single PO dose pharmacokinetic data. The AUC0-∞ for 7-OH-CBD after single IV compared to single PO dose was not different, suggesting complete absorption of CBD from the formulation in MCT oil when administered with canned dog food.
Keywords: dog, Cannabidiol, pharmacokinetics, adverse effects, oral dosing, Intravenous dosing
Received: 07 Jan 2025; Accepted: 28 Feb 2025.
Copyright: © 2025 Kitts-Morgan, Sams and Muir. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Susanna Elizabeth Kitts-Morgan, College of Veterinary Medicine, Lincoln Memorial University, Harrogate, United States
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Research integrity at Frontiers
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.